Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Institutes of Health, through the National Center for Advancing Translational Science, is forecasting an opportunity titled Screening for Conditions by Electronic Nose Technology (SCENT III). This initiative aims to develop advanced electronic nose technologies that mimic the human olfactory system to create a robust, noninvasive diagnostic platform. By focusing on the detection and analysis of volatile organic compound signatures from human skin using systems engineering and artificial intelligence, the project seeks to provide real-time, in situ monitoring of disease onset, progression, and resolution. These technologies are intended to complement traditional invasive and expensive diagnostic procedures, such as blood analysis, to accelerate the prevention and treatment of various medical conditions. The effort is authorized under the Cures Acceleration Network and is categorized under NAICS code 541715. This specific forecast indicates that clinical trials are not allowed as part of this development phase.
General Info
Place of Performance
Not specifiedSet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. A previous iteration demonstrated the feasibility of developing safe and effective biosensing technologies for volatile organic compound (VOC) signatures from human skin through systems engineering and artificial intelligence. VOCs are biomarkers that underlie the effects of a wide array of diseases. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease.
NCATS’ vision is to bring more treatments for all people more quickly. The electronic nose platform is noninvasive and makes diagnosis in real time, in situ. This NOFO seeks to improve the translation of existing knowledge for the prevention and treatment of various diseases conditions.
Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Health And Human Services → National Institutes Of Health
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
